Kostev Karel, Bauer Anna, Jacob Louis
Int J Clin Pharmacol Ther. 2019 Apr;57(4):182-187. doi: 10.5414/CP203371.
The goal of the present study was to investigate lines of therapy with biological drugs in patients followed in dermatology, gastroenterology, and rheumatology practices in Germany.
The study included patients aged 18 years or over who had received a biological therapy in dermatology, gastroenterology, or rheumatology practices in Germany in 2017 (index date). The primary outcome of the study was the prevalence of different lines of therapy (first-, second-, third-, and at least fourth-line therapies) by type of practice, age, and gender. The second outcome was the association between basic characteristics (type of practice, age, and gender) and lines of therapy with biological drugs.
The present study included 27,816 individuals. The mean age (SD) at index date was 50.7 years (15.4 years). Biological drugs were prescribed as first-line therapies in 60% of patients (dermatology 73%, gastroenterology 61%, and rheumatology 56%). The prevalence of first-line therapies ranged from 57% in individuals aged 41 - 50 years to 65% in those aged 18 - 30 years. Furthermore, 56% of women and 61% of men were prescribed biological drugs as first-line therapies. Finally, the likelihood of being prescribed biological drugs as second-, third-, or at least fourth-line therapies was significantly associated with being followed in a rheumatology or gastroenterology practice, older age, and female gender.
CONCLUSION: Biological drugs were prescribed as first-line therapies in most cases. The type of practice as well as the patient's age and gender had a significant impact on lines of therapy with biological drugs. .
本研究的目的是调查德国皮肤科、胃肠病科和风湿病科门诊中使用生物药物的治疗方案。
该研究纳入了2017年(索引日期)在德国皮肤科、胃肠病科或风湿病科门诊接受过生物治疗的18岁及以上患者。该研究的主要结局是按科室类型、年龄和性别划分的不同治疗方案(一线、二线、三线和至少四线治疗)的患病率。第二个结局是基本特征(科室类型、年龄和性别)与生物药物治疗方案之间的关联。
本研究共纳入27,816名个体。索引日期时的平均年龄(标准差)为50.7岁(15.4岁)。60%的患者接受生物药物作为一线治疗(皮肤科73%,胃肠病科61%,风湿病科56%)。一线治疗的患病率在41 - 50岁个体中为57%,在18 - 30岁个体中为65%。此外,56%的女性和61%的男性接受生物药物作为一线治疗。最后,接受二线、三线或至少四线生物药物治疗的可能性与在风湿病科或胃肠病科门诊就诊、年龄较大以及女性性别显著相关。
大多数情况下生物药物被用作一线治疗。科室类型以及患者的年龄和性别对生物药物治疗方案有显著影响。